PU¶PubMed·Journal article·Research (general)·2w agoIncidence and characteristics of teprotumumab-associated ototoxicity in thyroid eye disease: A systematic review and meta-analysisAudiologists and ENTs should be aware that teprotumumab carries a quantifiable ototoxicity risk; patients receiving this drug for thyroid eye disease warrant hearing monitoring, and audiologists may be asked to provide baseline and follow-up audiometric testing.
PU¶PubMed·Journal article·Research (general)·3w agoTeprotumumab for dysthyroid optic neuropathy: early functional and structural improvement in a retrospective case seriesThyroid disorders intersect with audiology through ototoxicity (hearing damage from medications) and autoimmune hearing loss; understanding emerging systemic treatments for thyroid disease broadens the clinical context audiologists may encounter in shared patients.＋Save
PU¶PubMed·Journal article·Research (general)·5mo agoFive year of post-marketing safety of teprotumumab: A disproportionality analysis of the FDA adverse event reporting systemAudiologists should be aware that teprotumumab is associated with hearing-related adverse events in post-marketing data; patients on this drug warrant audiological monitoring, though causality and rates require further prospective study.＋Save
